Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (Nasdaq: ECOR) will report first-quarter financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026.
Management will host a webinar at 4:30 PM EDT to review results and answer questions; investors may join by dial-in or registration (webinar ID and passcode provided).
electroCore (Nasdaq: ECOR) announced it will present at the Market Movers Investor Summit on May 5, 2026. Joshua Lev, Interim President and CFO, will deliver a company presentation at 12:20 PM ET and hold one-on-one meetings at the Bank of New York, 48 Wall Street, New York.
Requests for invitations are available at www.marketmoverssummit.com. The summit features presentations, fireside chats, one-on-ones, and networking across May 4–5, 2026.
electroCore (Nasdaq: ECOR) is featured in the documentary Hacking the Vagus Nerve, part of the Healing Journeys series, highlighting clinical and consumer uses of non-invasive vagus nerve stimulation (nVNS).
The film includes expert commentary from Dr. Peter S. Staats and showcases electroCore products: prescription gammaCore, Truvaga Plus, and TAC-STIM, and discusses ongoing work in PTSD, Long COVID, and stress-related conditions. The documentary is available at the Healing Journeys website.
electroCore (Nasdaq: ECOR) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Management presentation is scheduled for 2:15 pm ET, led by Joshua Lev, Interim President and Chief Financial Officer.
Investors can request one-on-one meetings via their Needham representative or by emailing investors@electrocore.com.
electroCore (Nasdaq: ECOR) announced enrollment of the first eight patients in an investigator-led study evaluating gammaCore non-invasive vagus nerve stimulation (nVNS) as an adjunctive treatment for PTSD.
The study will enroll up to 40 adults, assess outcomes over a 12-week treatment period, and run approximately 10 months. Primary endpoints are treatment-related serious adverse events and change in CAPS-5 total score at 12 weeks. electroCore is providing an educational grant and devices.
electroCore (Nasdaq: ECOR) announced on April 1, 2026 the publication of a Frontiers in Neuroscience paper reporting a post-hoc analysis of 35 patients with chronic mild traumatic brain injury (mTBI) and comorbid PTSD. The analysis found adjunctive non-invasive vagus nerve stimulation (nVNS) significantly reduced overall symptom burden across cognitive, affective, and somatic domains.
According to the company, the study examined a high-symptom-burden cohort and adds to evidence supporting the therapeutic potential of nVNS for chronic mTBI with PTSD.
electroCore (NASDAQ: ECOR) announced two executive hires and inducement equity grants effective April 2026. Seth Abrams will join as VP, Sales on April 1, 2026, and Michael Fox will join as Chief Operating Officer on April 13, 2026.
The Compensation Committee granted 30,000 RSUs to Abrams and 70,000 RSUs to Fox under NASDAQ Listing Rule 5635(c)(4). The RSUs vest one-third on each of the first, second and third anniversaries of grant and will be settled in common stock upon vesting, subject to continued employment.
electroCore (Nasdaq: ECOR) announced issuance of two new U.S. patents that expand protection for its non-invasive vagus nerve stimulation (nVNS) platforms.
The patents (U.S. Pat. No. 12,208,263 on Jan 28, 2026; U.S. Pat. No. 12,213,795 on Feb 4, 2026) broaden claims for device positioning, therapy adjustment, data storage, and remote monitoring. The company says its estate now exceeds 160 issued U.S. patents and that patent terms may extend to at least 2039, supporting exclusivity into the 2040s.
electroCore (Nasdaq: ECOR) reported record full year 2025 net sales of $32.0 million, up ~27% from $25.2 million in 2024, driven by U.S. prescription growth and a 97% rise in general wellness sales.
GAAP net loss was $14.0 million; adjusted EBITDA loss improved to $8.7 million. Total cash was $11.6 million at December 31, 2025. The company provided 2026 revenue guidance of approximately 30% growth and announced CEO Dan Goldberger will retire April 1, 2026, with Joshua Lev named interim President and Michael Fox hired as COO.
electroCore (Nasdaq: ECOR) management will participate in the 38th Annual Roth Conference March 22–24, 2026, at the Ritz-Carlton in Laguna Niguel, California. CFO Joshua Lev will host one-on-one investor meetings. Investors can schedule via their Roth representative or by emailing investors@electrocore.com.